Table 4.
Expression profile of LINC-ROR and SALL4 in different clinicopathological features of the enrolled GC patients
| Factor |
LINC-ROR
|
p
value |
SALL4
|
p value |
Coexpression of markers
( p value ) |
||
|---|---|---|---|---|---|---|---|
| ─ / ↑ (%) | ↓ (%) | ─ / ↑ (%) | ↓ (%) | ||||
| Sex Male Female |
26 (30.2) 13 (15.1) |
37 (43) 10 (11.6) |
0.05 * | 25 (29) 12 (13.9) |
38 (44.1) 11 (12.7) | NS | 0.246 0.031* |
| Differentiation | |||||||
| PD MD WD |
12 (13.9) 30 (34.8) 5 (5.8) |
8 (9.3) 25 (29) 6 (6.9) |
NS | 10 (11.6) 23 (26.7) 4 (4.6) |
10 (11.6) 32 (37.2) 7 (8.1) |
NS |
0.07
0.02* 0.48 |
| Lymph node metastasis (N) | |||||||
| N0 N1 N2 N3 |
7 (8.1) 17 (19.7) 11 (12.7) 4 (4.6) |
6 (6.9) 23 (26.7) 15 (17.4) 3 (3.4) |
NS | 7 (8.1) 14 (16.2) 14 (16.2) 2 (2.3) |
6 (6.9) 26 (30.2) 12 (13.9) 5 (5.8) |
NS |
0.61
0.19 0.13 0.7 |
| Grade | |||||||
| I II III |
7 (8.1) 28 (32.5) 12 (13.9) |
6 (6.9) 25 (29) 8 (9.3) |
NS | 6 (6.9) 21 (24.4) 10 (11.6) |
7 (8.1) 32 (37.2) 10 (11.6) |
NS |
0.62
0.023* 0.081 |
| Stage of tumor progression | |||||||
| I II III IV |
4 (4.6) 5 (5.8) 33 (38.3) 5 (5.8) |
3 (3.4) 10 (11.6) 17 (19.7) 9 (10.4) |
0.029 * | 5 (5.8) 5 (5.8) 22 (25.5) 5 (5.8) |
2 (2.3) 10 (11.6) 28 (32.55) 9 (10.4) |
NS |
0.16
0.23 0.34 0.59 |
| Depth of tumor invasion (T) | |||||||
| T2 T3 T4 |
11 (12.7) 26 (30.2) 10 (11.6) |
11(12.7) 10 (11.6) 2 (2.3) |
NS | 9 (10.4) 20 (23.25) 8 (9.3) |
13 (15.11) 27 (31.39) 9 (10.4) |
NS |
0.002
*
0.96 0.76 |
| Tumor type | |||||||
| Intestinal Diffuse Mixed |
33 (38.3) 11 (12.7) 3 (3.4) |
27 (31.3) 11 (12.7) 3 (3.4) |
0.05 * | 25 (29) 8 (9.3) 4 (4.6) |
35 (40.6) 13 (15.11) 1 (1.1) |
NS | 0.19 0.14 0.75 |
| Location | |||||||
| Cardiac Noncardiac |
23 (26.7) 24 (27.9) |
14 (16.2) 25 (29) |
0.048 * | 15 (17.4) 22 (25.5) |
22 (25.5) 27 (31.39) |
NS | 0.77 0.021* |
| H. pylori (16s rRNA/UreC) | |||||||
| Positive Negative |
23 (26.7) 24 (27.9) |
19 (22) 20 (23.2) |
NS | 24 (27.9) 13 (15.1) |
19 (22) 30 (34.8) |
0.047 * |
0.03
*
0.96 |
| H. pylori (CagA) | |||||||
| Positive Negative |
23 (26.7) 24 (27.9) |
25 (29) 14 (16.2) |
NS | 12 (13.9) 25 (29) |
23 (26.7) 26 (30.2) |
0.036 * |
0.041
*
0.87 |
PD, poorly differentiated; MD, moderately differentiated; WD, well differentiated; N0, no. of regional lymph node metastasis; N1, metastasis in one to two regional lymph nodes; N2, metastasis in three to six regional lymph nodes; N3, metastasis in seven or more regional lymph nodes; NS, non-significant correlation